Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001782268 | SCV002016636 | likely pathogenic | not provided | 2021-09-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003464141 | SCV004192390 | likely pathogenic | Bifunctional peroxisomal enzyme deficiency | 2023-08-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003772152 | SCV004588725 | pathogenic | Bifunctional peroxisomal enzyme deficiency; Perrault syndrome | 2023-08-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with HSD17B4-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe462Serfs*24) in the HSD17B4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HSD17B4 are known to be pathogenic (PMID: 11810648, 16385454, 20673864). |